Biomarker Testing In Oncology
The use of biomarkers in oncology has been growing since the first wave of targeted therapies in the late 1990s, which included Gleevec (Acute Lymphoblastic Leukaemia, ALL) and Herceptin (Breast Cancer). Solid cancer patients see higher testing rates than haematological (haem) cancer patients, as a smaller number of predictive biomarkers linking to targeted therapies have been identified for haem cancers. We see greater evolution of testing within certain indications with high incidence and high unmet need. Solid cancers which show high uptake of several different biomarker tests are Breast Cancer and Non-Small Cell Lung Cancer (NSCLC). Certain haem cancers show high testing rates for fewer key biomarkers, such as ALL and AML. Download the available infographic to learn more.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.